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Résumé en
anglais
Objectives: The aims of this study were (i) to investigate the population
pharmacokinetics of tacrolimus in renal transplant recipients, including the influence
of biological and pharmacogenetic covariates; and (ii) to develop a Bayesian estimator
able to reliably estimate the individual pharmacokinetic parameters and inter-dose
area under the blood concentration-time curve (AUC) from 0 to 12 hours (AUC12) in
renal transplant patients. Methods: Full pharmacokinetic profiles were obtained from
32 renal transplant patients at weeks 1 and 2, and at months 1, 3 and 6 post-
transplantation. The population pharmacokinetic analysis was performed using the
nonlinear mixed-effect modelling software NONMEM® version VI. Patients’
genotypes were characterized by allelic discrimination for PXR −25385C>T genes.
Results: Tacrolimus pharmacokinetics were well described by a two-compartment
model combined with an Erlang distribution to describe the absorption phase, with
low additive and proportional residual errors of 1.6 ng/mL and 9%, respectively. Both
the haematocrit and PXR −25385C>T single nucleotide polymorphism (SNP) were
identified as significant covariates for apparent oral clearance (CL/F) of tacrolimus,
which allowed improvement of prediction accuracy. Specifically, CL/F decreased
gradually with the number of mutated alleles for the PXR −25385C>T SNP and was
inversely proportional to the haematocrit value. However, clinical criteria of
relevance, mainly the decrease in interindividual variability and residual error, led us
to retain only the haematocrit in the final model. Maximum a posteriori Bayesian
forecasting allowed accurate prediction of the tacrolimus AUC12 using only three
sampling times (at 0 hour [predose] and at 1 and 3 hours postdose) in addition to the
haematocrit value, with a nonsignificant mean AUC bias of 2% and good precision
(relative mean square error = 11%). Conclusion: Population pharmacokinetic analysis
of tacrolimus in renal transplant recipients showed a significant influence of the
haematocrit on its CL/F and led to the development of a Bayesian estimator
compatible with clinical practice and able to accurately predict tacrolimus individual
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